FY2024 EPS Estimates for Chemours Reduced by Zacks Research

The Chemours Company (NYSE:CC) – Equities researchers at Zacks Research dropped their FY2024 earnings per share (EPS) estimates for Chemours in a research report issued to clients and investors on Tuesday, January 14th. Zacks Research analyst R. Department now forecasts that the specialty chemicals company will post earnings per share of $1.20 for the year, down from their previous forecast of $1.28. The consensus estimate for Chemours’ current full-year earnings is $1.21 per share. Zacks Research also issued estimates for Chemours’ Q1 2026 earnings at $0.61 EPS.

Chemours (NYSE:CC) last posted its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. The firm’s revenue was up .9% compared to the same quarter last year.

A number of other brokerages have also commented on CC. Morgan Stanley lowered their price objective on Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday. Barclays boosted their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $25.00 target price on shares of Chemours in a report on Thursday, December 12th. The Goldman Sachs Group lowered their price target on Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Finally, Mizuho cut their price objective on Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $23.75.

Chemours Price Performance

CC opened at $19.11 on Friday. Chemours has a 1 year low of $15.10 and a 1 year high of $32.48. The stock has a fifty day moving average price of $19.14 and a 200 day moving average price of $19.79. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 38.21 and a beta of 1.83.

Hedge Funds Weigh In On Chemours

Large investors have recently modified their holdings of the stock. Appian Way Asset Management LP bought a new position in Chemours in the 3rd quarter worth approximately $34,151,000. Vision One Management Partners LP acquired a new stake in Chemours in the third quarter worth about $28,252,000. Marshall Wace LLP lifted its position in Chemours by 23.8% during the 2nd quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock valued at $158,213,000 after purchasing an additional 1,347,710 shares during the period. Khrom Capital Management LLC grew its holdings in Chemours by 54.6% during the 2nd quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock worth $78,016,000 after acquiring an additional 1,220,967 shares during the period. Finally, Scopia Capital Management LP acquired a new stake in shares of Chemours during the third quarter worth $13,623,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now owns 16,645 shares in the company, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.47% of the stock is owned by corporate insiders.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were issued a $0.25 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.23%. Chemours’s payout ratio is presently 200.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.